Published in Nat Rev Drug Discov on June 01, 2007
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci (2013) 3.11
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience (2008) 2.55
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke (2011) 2.37
The impact of the extracellular matrix on inflammation. Nat Rev Immunol (2010) 2.30
The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc Natl Acad Sci U S A (2009) 2.15
Emerging principles in protease-based drug discovery. Nat Rev Drug Discov (2010) 2.05
VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood (2012) 1.94
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
POVME: an algorithm for measuring binding-pocket volumes. J Mol Graph Model (2010) 1.75
Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.62
Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. Am J Physiol Cell Physiol (2013) 1.62
Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov (2014) 1.57
Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev (2009) 1.49
Applications of chitin and its derivatives in biological medicine. Int J Mol Sci (2010) 1.45
Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet (2009) 1.44
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Zymography methods for visualizing hydrolytic enzymes. Nat Methods (2013) 1.31
Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26
Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology (2009) 1.25
Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis (2013) 1.20
Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med (2011) 1.19
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop (2009) 1.16
Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J Biol Chem (2007) 1.12
Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus. Clin Orthop Relat Res (2008) 1.11
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) (2014) 1.10
Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs (2012) 1.10
Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes (2009) 1.09
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. Nat Chem Biol (2009) 1.07
New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol (2012) 1.05
Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol (2010) 1.02
The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol (2013) 1.01
Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential. J Chem Theory Comput (2012) 1.01
Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology (2007) 1.00
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 1.00
Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS One (2013) 1.00
Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther (2008) 0.99
Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis (2015) 0.99
Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci (2009) 0.99
Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar Drugs (2009) 0.99
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol (2011) 0.98
Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci (2015) 0.97
MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J Biol Chem (2008) 0.97
Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97
Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum Mol Genet (2011) 0.96
Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. Curr Opin Pharmacol (2008) 0.96
Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One (2010) 0.96
Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules (2012) 0.95
Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther (2008) 0.95
Selective water-soluble gelatinase inhibitor prodrugs. J Med Chem (2011) 0.95
IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J Cell Biochem (2010) 0.95
Metalloproteases and tendinopathy. Muscles Ligaments Tendons J (2013) 0.95
Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proc Natl Acad Sci U S A (2009) 0.94
MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses. PLoS One (2008) 0.93
Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. Int J Clin Exp Med (2011) 0.93
Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors. J Mol Recognit (2010) 0.93
The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med (2008) 0.93
Chemical biology for understanding matrix metalloproteinase function. Chembiochem (2012) 0.92
Bone marrow-derived matrix metalloproteinase-9 is associated with fibrous adhesion formation after murine flexor tendon injury. PLoS One (2012) 0.92
Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am J Pathol (2009) 0.91
Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am J Pathol (2008) 0.91
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One (2015) 0.90
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin Exp Immunol (2013) 0.90
Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J Biol Chem (2011) 0.90
Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes. Mol Pharm (2012) 0.90
Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. J Biol Chem (2011) 0.90
Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease. Infect Immun (2013) 0.90
Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology (2012) 0.90
Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders. Biomol Ther (Seoul) (2012) 0.89
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Effect of cold ischemia/reperfusion injury and/or shear stress with portal hypertension on the expression of matrix metalloproteinase-9. Ann Gastroenterol (2012) 0.88
Evaluation of 11 scoring functions performance on matrix metalloproteinases. Int J Med Chem (2014) 0.88
Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res (2010) 0.88
Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy. PLoS One (2013) 0.88
Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine (2014) 0.87
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets (2013) 0.87
Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J (2010) 0.87
Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm (2015) 0.87
Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem Res Int (2012) 0.87
Cardiosome mediated regulation of MMP9 in diabetic heart: role of mir29b and mir455 in exercise. J Cell Mol Med (2015) 0.86
A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta (2013) 0.86
Altered circulating levels of matrix metalloproteinases and inhibitors associated with elevated type 2 cytokines in lymphatic filarial disease. PLoS Negl Trop Dis (2012) 0.86
Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors. Chem Biol Drug Des (2011) 0.86
Bioresponsive nanosensors in medical imaging. J R Soc Interface (2009) 0.85
PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One (2012) 0.85
Inhibitor of PI3Kγ ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells. Br J Pharmacol (2011) 0.84
Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity? Fluids Barriers CNS (2014) 0.84
Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets (2013) 0.84
Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J (2015) 0.84
Cloning and expression of ADAM-related metalloproteases in equine laminitis. Vet Immunol Immunopathol (2008) 0.84
A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci Rep (2015) 0.83
Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets. Pain Res Treat (2012) 0.83
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle (2012) 0.83
A macrophage cell model for selective metalloproteinase inhibitor design. Chembiochem (2008) 0.83
Matrix metalloproteinase 9 opposes diet-induced muscle insulin resistance in mice. Diabetologia (2013) 0.83
A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations. Mediators Inflamm (2014) 0.82
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci (2013) 3.11
Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med (2006) 2.51
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol (2013) 2.09
Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure (2007) 2.05
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood (2008) 1.98
VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood (2012) 1.94
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem (2003) 1.93
The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol (2007) 1.90
Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem (2006) 1.79
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem (2002) 1.55
Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur J Immunol (2014) 1.52
Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci U S A (2002) 1.50
Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol (2010) 1.49
Chromosome 7q21-22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. J Neuroimmunol (2002) 1.48
Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci (2003) 1.45
Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell (2010) 1.39
The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem (2006) 1.36
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med (2008) 1.34
Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun (2003) 1.33
Zymography methods for visualizing hydrolytic enzymes. Nat Methods (2013) 1.31
Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol (2006) 1.31
Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke (2009) 1.26
GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res (2005) 1.24
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol (2006) 1.21
Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol (2011) 1.20
CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol (2008) 1.20
Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol (2004) 1.15
Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab (2005) 1.14
Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am J Respir Crit Care Med (2010) 1.14
Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem (2009) 1.14
Avian papillomaviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus. BMC Microbiol (2002) 1.11
The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1beta and is down-regulated by interferon-gamma: comparison with interleukin-8/CXCL8. Lab Invest (2003) 1.10
Direct visualization of protease action on collagen triple helical structure. PLoS One (2010) 1.08
PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol (2003) 1.07
Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J Leukoc Biol (2004) 1.06
Hemozoin induces lung inflammation and correlates with malaria-associated acute respiratory distress syndrome. Am J Respir Cell Mol Biol (2013) 1.06
TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest (2006) 1.04
Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem Pharmacol (2005) 1.03
Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol (2002) 1.03
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood (2010) 1.02
The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J Mol Biol (2008) 1.02
Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. Eur J Immunol (2005) 0.99
Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. FASEB J (2005) 0.99
Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur J Immunol (2009) 0.97
Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates. Integr Biol (Camb) (2009) 0.96
Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther (2011) 0.96
Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils. Immunobiology (2007) 0.96
Pathogenesis of malaria-associated acute respiratory distress syndrome. Trends Parasitol (2013) 0.96
Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. Immunobiology (2009) 0.96
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther (2006) 0.96
The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res (2006) 0.96
Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. Immunobiology (2006) 0.95
Chemokine-protease interactions in cancer. Semin Cancer Biol (2004) 0.94
Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Lab Invest (2006) 0.94
Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. Acta Diabetol (2011) 0.94
A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta (2006) 0.93
Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin (2005) 0.93
Neutrophil elastase activity compensates for a genetic lack of matrix metalloproteinase-9 (MMP-9) in leukocyte infiltration in a model of experimental peritonitis. J Leukoc Biol (2008) 0.92
Interferon-γ orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J Interferon Cytokine Res (2011) 0.92
Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses. Antimicrob Agents Chemother (2005) 0.92
Enzymatic degradation of adhesive-dentin interfaces produced by mild self-etch adhesives. Eur J Oral Sci (2010) 0.92
CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology (2011) 0.91
Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol (2007) 0.90
Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J Biol Chem (2011) 0.90
CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8. J Leukoc Biol (2009) 0.90
Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J Virol (2008) 0.90
Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry (2008) 0.89
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization. Blood (2003) 0.89
Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes. Adv Exp Med Biol (2003) 0.89
Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest (2002) 0.89
Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Haematologica (2009) 0.89
Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb Chem High Throughput Screen (2006) 0.88
Gastric gelatinase B/matrix metalloproteinase-9 is rapidly increased in Helicobacter felis-induced gastritis. FEMS Immunol Med Microbiol (2007) 0.87
Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. J Pathol (2009) 0.86
Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. Mol Vis (2010) 0.86